Background:
Pretransplant diabetes and new-onset diabetes after transplant (NODAT) are known risk factors for vascular events after kidney transplantation, but the incidence and magnitude of the risk of major adverse cardiovascular events (MACE) and cardiac deaths remain uncertain in recent era.
Methods:
A population cohort study of kidney transplant recipients identified using data from linked administrative healthcare databases from Ontario, Canada. The incidence rates of MACE (expressed as events with 95% confidence interval [95% CI] per 1000 person-years were reported according to diabetes status of pretransplant diabetes, NODAT, or no diabetes. Extended Cox regression model was used to examine the association between diabetes status, MACE, and cardiac death.
Results:
Of 5248 recipients, 1973 (38%) had pretransplant diabetes, and 799 (15%) developed NODAT with a median follow-up of 5.5 y. The incidence rates (95% CI) of MACE for recipients with pretransplant diabetes, NODAT, and no diabetes between 1 and 3 y posttransplant were 38.1 (32.1-45.3), 12.6 (6.3-25.2), and 11.8 (9.2-15.0) per 1000 person-years, respectively. Compared with recipients with pretransplant diabetes, recipients with NODAT experienced a lower risk of MACE (adjusted hazard ratio, 0.59; 95% CI, 0.47-0.74) but not cardiac death (adjusted hazard ratio, 0.97; 95% CI, 0.61-1.55). The rate of MACE and cardiac death was lowest in patients without diabetes.
Conclusions:
Patients with pretransplant diabetes incur the greatest rate of MACE and cardiac deaths after transplantation. Having NODAT also bears high burden of vascular events compared with those without diabetes, but the magnitude of the increased rate remains lower than recipients with pretransplant diabetes.
Citing Articles
Association of glucagon-like peptide-1 receptor agonists with cardiovascular and kidney outcomes in type 2 diabetic kidney transplant recipients.
Lin L, Chen J, Huang T, Wu V
Cardiovasc Diabetol. 2025; 24(1):87.
PMID: 39984953
PMC: 11846168.
DOI: 10.1186/s12933-025-02649-0.
Impact of New-Onset Diabetes after Transplantation on Cardiovascular Risk and Mortality in Korea: A Nationwide Population-Based Study.
Park S, Koo B, Park S, Han K, Moon M
Diabetes Metab J. 2024; 49(1):117-127.
PMID: 39262290
PMC: 11788551.
DOI: 10.4093/dmj.2024.0078.
Association of Cardiopulmonary Hemodynamics and Outcomes in Pulmonary Hypertension Following Kidney Transplantation: A Multicenter Retrospective Cohort Study.
Jose A, Kumar S, Gorelik L, Friedman S, Flores A, Sese D
Chest. 2024; 166(6):1499-1510.
PMID: 39181378
PMC: 11638545.
DOI: 10.1016/j.chest.2024.08.013.
Prognostic impact of post-transplant diabetes mellitus in kidney allograft recipients: a meta-analysis.
Kanbay M, Siriopol D, Guldan M, Ozbek L, Topcu A, Siriopol I
Nephrol Dial Transplant. 2024; 40(3):554-576.
PMID: 39134508
PMC: 11879034.
DOI: 10.1093/ndt/gfae185.
Effect of post-transplant diabetes mellitus on cardiovascular events and mortality: a single-center retrospective cohort study.
Unluturk U, Yildirim T, Savas M, Oguz S, Firlatan B, Yuce D
Endocrine. 2024; 85(2):695-703.
PMID: 38491339
DOI: 10.1007/s12020-024-03770-y.
Association between diabetic status and risk of all-cause and cause-specific mortality on dialysis following first kidney allograft loss.
Samarasinghe A, Wong G, Teixeira-Pinto A, Johnson D, Hawley C, Pilmore H
Clin Kidney J. 2024; 17(3):sfad245.
PMID: 38468698
PMC: 10926326.
DOI: 10.1093/ckj/sfad245.
A Multi-Step Precision Pathway for Predicting Allograft Survival in Heterogeneous Cohorts of Kidney Transplant Recipients.
Zhang Y, Deng D, Muller S, Wong G, Yang J
Transpl Int. 2023; 36:11338.
PMID: 37767525
PMC: 10520244.
DOI: 10.3389/ti.2023.11338.
Global Epidemiology, Health Outcomes, and Treatment Options for Patients With Type 2 Diabetes and Kidney Failure.
Phillips J, Chen J, Ooi E, Prunster J, Lim W
Front Clin Diabetes Healthc. 2023; 2:731574.
PMID: 36994340
PMC: 10012134.
DOI: 10.3389/fcdhc.2021.731574.
Characterization, evolution and risk factors of diabetes and prediabetes in a pediatric cohort of renal and liver transplant recipients.
Welsch S, Mailleux V, le Hardy de Beaulieu P, Ranguelov N, Godefroid N, Robert A
Front Pediatr. 2023; 11:1080905.
PMID: 36824650
PMC: 9941739.
DOI: 10.3389/fped.2023.1080905.
Impact of Post-Transplant Diabetes Mellitus on Survival and Cardiovascular Events in Kidney Transplant Recipients.
Jeon J, Han-Bit S, Park B, Lee N, Kim H, Kim D
Endocrinol Metab (Seoul). 2023; 38(1):139-145.
PMID: 36746391
PMC: 10008662.
DOI: 10.3803/EnM.2022.1594.
Cardiovascular outcomes in children with Kawasaki disease: a population-based cohort study.
Robinson C, Chanchlani R, Gayowsky A, Brar S, Darling E, Demers C
Pediatr Res. 2022; 93(5):1267-1275.
PMID: 36380069
DOI: 10.1038/s41390-022-02391-3.
Impact of diabetes mellitus developing after kidney transplantation on patient mortality and graft survival: a meta-analysis of adjusted data.
Lin H, Yan J, Yuan L, Qi B, Zhang Z, Zhang W
Diabetol Metab Syndr. 2021; 13(1):126.
PMID: 34717725
PMC: 8557540.
DOI: 10.1186/s13098-021-00742-4.
Safety and Efficacy of Sodium-glucose Cotransporter 2 Inhibitors in Kidney Transplant Recipients With Pretransplant Type 2 Diabetes Mellitus: A Retrospective, Single-center, Inverse Probability of Treatment Weighting Analysis of 85 Transplant....
Hisadome Y, Mei T, Noguchi H, Ohkuma T, Sato Y, Kaku K
Transplant Direct. 2021; 7(11):e772.
PMID: 34646935
PMC: 8500668.
DOI: 10.1097/TXD.0000000000001228.